IMO, the 1/2 bil$ PP is asking for is their projected return from the India and China market over say the next 10 years. I suspect they have not been given the product to begin testing by CYGX, for some unknown reason. Hoping this issue can be resolved out of court. Could be a big dilutional hit. A suit hanging over CYGX's head is a bad stench that will cause major pharma's to stand back for a while.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.